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Abstract Insulin acutely stimulated glucose uptake in rat
primary brown adipocytes in a PI3-kinase-dependent but
p70S6-kinase-independent manner. Since Akt represents an
intermediate step between these kinases, this study investigated
the contribution of Akt to insulin-induced glucose uptake by the
use of a chemical compound, ML-9, as well as by transfection
with a dominant-negative form of Akt (vAkt). Pretreatment with
ML-9 for 10 min completely inhibited insulin stimulation of (1)
Akt kinase activity, (2) Akt phosphorylation on the regulatory
residue Ser473 but not on Thr308, and (3) mobility shift in Akt1
and Akt2. However, ML-9 did not affect insulin-stimulated PI3-
kinase nor PKCj activities. In consequence, ML-9 precluded
insulin stimulation of glucose uptake and GLUT4 translocation
to plasma membrane (determined by Western blot), without any
effect on the basal glucose uptake. Moreover, vAkt impaired
insulin stimulation of glucose uptake and GFP-tagged GLUT4
translocation to plasma membrane in transiently transfected
immortalised brown adipocytes and HeLa cells, respectively.
Furthermore, ML-9 treatment for 6 h down-regulated insulin-
induced GLUT4 mRNA accumulation, without affecting
GLUT1 expression, in a similar fashion as LY294002. Indeed,
co-transfection of brown adipocytes with vAkt precluded the
transactivation of GLUT4-CAT promoter by insulin in a similar
fashion as a dominant-negative form of PI3-kinase. Our results
indicate that activation of Akt may be an essential requirement
for insulin regulation of glucose uptake and GLUT4 gene
expression in brown adipocytes. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Brown adipose tissue is a target tissue for insulin action,
specially during late foetal development when insulin pro-
motes both adipogenic and thermogenic di¡erentiation of pri-
mary cells, as well as displays survival e¡ects [1^3]. Glucose
transport in foetal brown adipocytes is maintained mainly by
the activity of the insulin-regulated glucose transporter
GLUT4, although the ubiquitous GLUT1 glucose transporter
is often expressed at appreciable levels together with GLUT4.
During foetal life, GLUT1 is expressed at high level in rat
brown adipose tissue, although GLUT4 mRNA expression
increases greatly at day 22 of foetal development concomitant
to the onset of di¡erentiation of the tissue [1]. Acute insulin
treatment stimulates glucose transport in adipocytes and my-
ocytes largely by mediating translocation of GLUT4 from an
intracellular compartment to the plasma membrane, as re-
viewed [4]. It is well established that activation of phosphati-
dylinositol (PI)3-kinase mediates GLUT4 redistribution to the
plasma membrane; overexpression of the catalytic subunit of
p110 produced GLUT4 translocation and increased glucose
uptake [5,6], and inhibition of PI3-kinase (either by chemical
inhibitors, or by microinjection of blocking p85 protein, or by
transfection with a dominant-negative mutant of p85) pre-
cluded insulin-induced GLUT4 translocation [7,8]. The targets
of PI3-kinase action are likewise controversial. Two classes of
Ser/Thr kinases have been proposed to act downstream of
PI3-kinase, Akt/PKB and the atypical protein kinase (PK) C
isoforms j and V (PKC j/V). Expression of a constitutively
active, membrane-bound form of Akt, using either stable or
inducible expression systems, resulted in persistent localisation
of GLUT4 at the plasma membrane and increased glucose
uptake in 3T3-L1 adipocytes [9,10] but did not promote
GLUT4 translocation or glucose transport in L6 myotubes
[11]. Experiments involving expression of a dominant-negative
Akt mutant are also controversial since both inhibition of
insulin-stimulated GLUT4 translocation [12] or no e¡ect
have been described [13]. Very recently, ML-9 has been char-
acterised as a chemical inhibitor of Akt activity, that prevents
some of the metabolic e¡ects of insulin in isolated rat fat cells
[14]. Expression of PKCj or V are also reported to induce
GLUT4 translocation, whereas expression of a dominant-in-
terfering PKCj inhibited GLUT4 translocation in 3T3L1 cells
[15,16]. Our previous work showed that PI3-kinase and PKCj
could be involved in IGF-I/insulin-stimulation of glucose up-
take in foetal brown adipocyte primary cultures [17,18].
Meanwhile Akt activation seems to be an absolute require-
ment for insulin rescue from apoptosis for these cells [19], the
implication of Akt in insulin-induced glucose uptake in brown
adipocytes has not been reported yet.
Although in vivo studies clearly indicate that GLUT4 ex-
pression in insulin-responsive tissues is under insulin and/or
metabolic control [20,21], experiments using cultured fat cells
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had failed to establish a stimulatory role of insulin in GLUT4
expression [22], and a positive e¡ect of insulin on GLUT4
gene expression had only been observed when dexamethasone
was also present [23,24]. However, in rat cardiomyocytes there
are evidences of a direct e¡ect of insulin on GLUT4 tran-
scription [25]. In this regard, we have previously described
that insulin up-regulated GLUT4 gene expression in brown
adipocytes in a PI3-kinase-dependent manner [26]. Further-
more, Akt mediated the expression of certain genes, including
GLUT3 and GLUT1 [27,28]. Whether Akt could be mediat-
ing chronic insulin e¡ects on GLUT4 gene expression remains
to be established. The studies described herein propose that
insulin regulation on both glucose uptake and GLUT4 gene
expression in foetal brown adipocytes is produced throughout
the activation of Akt.
2. Materials and methods
2.1. Materials
1-(5-Chloronaphthalenesulfonyl)-1H-hexahydro-1,4-diazepine, also
known as ML-9, was purchased from Alexis Co (Switzerland).
LY294002 and rapamycin were from Calbiochem (Calbiochem-Nova-
biochem Intl, La Jolla, CA, USA). Insulin and bovine serum albumin
(BSA) (fraction V, essentially fatty acid free) were from Sigma Chem-
ical Co (St. Louis, MO, USA). Foetal calf serum (FCS), phosphate-
bu¡ered saline (PBS) and culture media were from Imperial Labora-
tories (Hampshire, UK). Trizol was from Gibco BRL (Life Technol-
ogies). Nylon membranes were GeneScreen1 (NEN Research Prod-
ucts, Boston, MA, USA). Autoradiographic ¢lms were Kodak X-
O-MAT/AR (Eastman Kodak Co, Rochester, NY, USA). 2-Deoxy-
D-[1-3H]glucose (11.0 Ci/mmol), [K-32P]dCTP (3000 Ci/mmol),
[Q-32P]ATP (3000 Ci/mmol), [14C]chloramphenicol and the multi-
primer DNA-labelling system kit were purchased from Amersham
(Aylesbury, UK). All other reagents used were of the purest grade
available. The cDNAs used as probes were GLUT4/GLUT1 [29]. The
MBS mammalian transfection kit and pCMVL-galactosidase (L-gal)
were supplied by Stratagene. The rabbit anti-GLUT1 and GLUT4
antibodies were supplied by Chemicon Inc (Tamacula, CA, USA).
The anti-Caveolin-1 (N-20) antibody was from Santa Cruz Biotech-
nology (Palo Alto, CA, USA). The anti-phospho-speci¢c Akt (Ser473)
and phospho-Akt (Thr308) antibodies, the anti-phospho-speci¢c
p70S6-kinase (Thr421/Ser424) antibody and the anti-total Akt anti-
body were purchased by New England Biolabs (Beverly, MA, USA).
The antibodies against Akt1 and Akt2 were from Upstate Biotechnol-
ogy (Lake Placid, NY, USA). The anti-PKCj antibody was purchased
from Gibco BRL (Life Technologies). For anti-Tyr(P) immunoprecip-
itation, a monoclonal antibody (Py72) was the generous gift of Dr.
E. Rozengurt (Imperial Cancer Research Foundation, London, UK).
2.2. Cell culture
Brown adipocytes were obtained from interscapular brown adipose
tissue of 20-day Wistar rat foetuses and isolated by collagenase dis-
persion as described [1]. Cells were plated at 1U106 cells/60 mm or at
4U106 cells/100-mm diameter tissue culture dishes in minimal essen-
tial medium with Earle’s salts (MEM) supplemented with 10% FCS.
After 4 h of culture at 37‡C, cells were rinsed twice with PBS and 70%
of the initial cells attached to the dish forming a monolayer. Cells
were maintained for 20 h in a serum-free medium supplemented with
0.2% (w/v) BSA before starting di¡erent treatments. For transfection
experiments with primary brown adipocytes, cells were cultured for
24 h in the presence of 10% FCS prior to transfection. For trans-
fection experiments we have also used a SV40 large T antigen-immor-
talised brown adipocyte cell line (MB 4.9.2) and HeLa cells, cultured
as previously described [3].
2.3. Measurement of the glucose transport
Glucose transport was measured in duplicated dishes from four
independent experiments as previously described [17].
2.4. Subcellular fractionation
Cells were washed with ice-cold PBS and scraped in homogenisa-
tion bu¡er containing: 20 mM Tris^HCl, pH 7.4, 2 mM EGTA, 2 mM
EDTA, 1 mM phenylmethylsulfonyl £uoride (PMSF), 10 mM L-mer-
captoethanol, 10 Wg/ml aprotinin, and 10 Wg/ml leupeptin. After
10 min incubation cells were homogenised with 30 strokes of a
Dounce-homogenised using a tight-¢tting pestle. Nuclei were pelleted
by centrifugation at 500Ug for 5 min, and the low speed supernatant
was centrifuged at 100 000Ug for 30 min. The high speed supernatant
constituted the internal membrane fraction. The pellet was washed
three times and extracted in ice-cold homogenisation bu¡er containing
1% Triton X-100 for 60 min. The Triton-soluble component (plasma
membrane fraction) was separated from the Triton-insoluble material
(cytoskeletal fraction) by centrifugation at 100 000Ug for 15 min.
Internal and plasma membrane fractions were kept at 370‡C before
protein quanti¢cation and Western blotting with GLUT4, GLUT1
and Caveolin-1 antibodies.
2.5. Western blotting
Cells were lysed as previously described [26] and cellular proteins
(20 Wg) were subjected to SDS^PAGE, transferred to Immobilon
membranes, blocked and incubated overnight with the primary anti-
bodies in 0.05% Tween-20, 1% non-fat dried milk in 10 mM Tris^HCl
and 150 mM NaCl, pH 7.5. Immunoreactive bands were visualised
using the enhanced chemiluminescence (ECL-plus) Western blotting
protocol (Amersham Pharmacia Biotech). Protein determination was
performed by the Bradford dye method, using Bio-Rad reagent and
BSA as a standard [30].
2.6. PI3-kinase activity
PI3-kinase activity was measured in the anti-Tyr(P) immunoprecip-
itates by in vitro phosphorylation of PI as described [17].
2.7. PKCj and PKB/Akt activities
Cells were extracted with lysis bu¡er (50 mM Tris, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM EGTA, 1 WM PMSF,
25 Wg/ml leupeptin and 25 Wg/ml aprotinin) and immunoprecipitated
with an anti-PKCj or anti-total Akt antiserum [17]. Immune com-
plexes were washed ¢ve times with ice-cold lysis bu¡er with 0.5 M
NaCl and two times with kinase bu¡er (35 mM Tris, pH 7.5, 10 mM
MgCl2, 0.5 mM EGTA, 1 WM Na3VO4). The kinase reaction was
performed in bu¡er containing 1 WCi of [Q32P]ATP, 60 WM ATP,
and 1 Wg of MBP as a substrate for 30 min at 30‡C, and was termi-
nated by the addition of 4USDS^PAGE sample bu¡er followed by
boiling for 5 min at 95‡C [31]. Samples were resolved in 12% SDS^
PAGE and gels were dried out and subjected to autoradiography.
2.8. RNA extraction and analysis
For Northern blot analysis of RNA, at the end of the culture time,
cells were washed twice with ice-cold PBS, and lysed directly with
Trizol following the protocol supplied by the manufacturer for total
RNA isolation. Total cellular RNA (10 Wg) was subjected to Northern
blot analysis, i.e. electrophoresed on 0.9% agarose gels containing 0.66
M formaldehyde, transferred to GeneScreen1 and cross-linked to the
membranes by UV light. Hybridisation was in 0.25 mM NaHP04, pH
7.2, 0.25 M NaCl, 100 Wg/ml denatured salmon sperm DNA, 7% SDS
and 50% deionised formamide, containing denatured 32P-labelled
cDNA (106 cpm/ml) for 24 h, at 42‡C, as previously described [26].
2.9. Transfection conditions
The following constructs were used for transfection experiments:
pSG5-PKB-CAAX encodes an Akt protein with dominant-negative
activity (vAkt). This construct is expressed under the control of the
early SV40 promoter for eukaryotic expression and was a generous
gift of B.M.Th. Burgering (Utrecht, The Netherlands) [31]. The dom-
inant-negative p85 construct (SrK-vp85), a protein that lacks the in-
ter-SH2 region required for binding to p110, thereby blocking activa-
tion of p110 was kindly provided by M. Kasuga (Kobe, Japan) [32].
GLUT4-CAT(chloramphenicol acetyltransferase) (where the CAT re-
porter gene is under the control of a 2400 bp full-length 5P-£anking
region of rat GLUT4 promoter, from positions 32212 to +164 rela-
tive to the transcription start site) was kindly provided by A. Zorzano
(Barcelona, Spain) [33]. GFP (green £uorescent protein)-tagged
GLUT4 was kindly provided by J. Tavare¤ (Bristol, UK) [34]. Primary
brown adipocytes were cultured for 24 h in the presence of 10% FCS
and then, transiently transfected according to the calcium phosphate-
mediated protocol with 10 Wg of GLUT4-CAT alone or combined
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with 10 Wg of vAkt or vp85 together with 2 Wg of pCMVL-gal (to
monitor transfection e⁄ciency). After 4 h of incubation, cells were
shocked with 3 ml of 15% glycerol^PBS for 2 min, washed, and
then fed with serum-free medium (either in the absence or presence
of insulin) for 24 h. Immortalised brown adipocytes (MB 4.9.2) or
HeLa cells cultured in 10% FCS were transiently transfected with 10
Wg of vAkt and/or 10 Wg GFP-GLUT4 as described above, using a
GFP vector to monitor transfection e⁄ciency when required. Then
cells were maintained for 24 h in 10% FCS, serum-starved overnight,
and the stimulated or not with insulin for 30 min.
2.10. CAT determination
After GLUT4-CAT transfection as described above, cells were cul-
tured for 24 h in a serum-free medium either in the absence or in the
presence of insulin, and then cells were harvested, and lysates were
prepared for CAT and L-gal activity assays, as previously described
[26]. The amount of substrate acetylated was directly quanti¢ed with a
radioimaging device (Fuji¢lm BAS-1000, Japan). CAT enzyme activ-
ity was expressed as a percentage of [14C]chloramphenicol acetylated
normalised to the internal control L-gal (assayed according to the
Stratagene protocol). Transfections were performed from four inde-
pendent experiments.
2.11. Translocation of GFP-GLUT4 to the plasma membrane
HeLa cells after GFP-tagged GLUT4 transfection as described
above were overnight serum-deprived and incubated with 500 nM
insulin for 30 min. Then, cells were analysed by £uorescence micros-
copy. Cells were scored as positive for GLUT4 translocation if they
were observed to have a ring of £uorescence at the periphery. Di¡er-
ent ¢elds were read blind by two independent investigators.
3. Results
3.1. Akt mediates insulin stimulation of glucose uptake and
GLUT4 translocation to the plasma membrane in brown
adipocytes
The fact that glucose transport is induced in foetal brown
adipocytes upon insulin stimulation [26], prompted us to in-
vestigate whether this e¡ect could be blocked by chemical
inhibitors of the insulin signalling pathway in those cells. Cells
were serum-deprived for 20 h and further treated or not with
10 WM LY294002 or 25 ng/ml rapamycin for 30 min before
being stimulated with insulin (10 nM) for further 30 min.
Glucose uptake was measured during the last 10 min of cul-
ture by incorporation of 2-deoxy-D-[1-3H]glucose into cells
and results are expressed as disintegrations per min/1U106
cells (Fig. 1A). Cells treated with insulin showed an increase
of 3-fold in glucose incorporation, compared with untreated
cells. The compound LY294002, that inhibited insulin-stimu-
lated PI3-kinase activity and consequently the phosphoryla-
tion of targets downstream PI3-kinase, such as Akt and
p70S6-kinase (Fig. 1B), completely abolished insulin e¡ects
on glucose uptake. The protein p70S6-kinase is an e¡ector
of PI3-kinase and is also phosphorylated in response to insu-
lin. However, blocking p70S6-kinase phosphorylation with
rapamycin, did not modify insulin-stimulated glucose incor-
poration (Fig. 1). These results indicate that insulin increases
glucose uptake through a pathway that involves PI3-kinase
and downstream targets others than p70S6-kinase, in brown
adipocytes.
Among the known targets downstream PI3-kinase, Akt and
PKCj have been reported to participate in insulin-induced
glucose transport [7,12,15]. In order to determine the signi¢-
cance of both kinases in the insulin pathway leading to glu-
cose incorporation in brown adipocytes we tested a com-
pound, ML-9, that has been recently characterised as an
inhibitor of Akt activity [14]. We ¢rst determined the e¡ect
of this inhibitor on insulin-stimulated PI3-kinase pathway in
brown adipocytes. Serum-starved cells were preincubated for
10 min with di¡erent doses of ML-9 before being treated with
insulin, and lysates were analysed for PI3-kinase, PKCj and
Akt activities as well as for phosphorylation of Akt and
p70S6-kinase. Cells were immunoprecipitated with anti-
Tyr(P), anti-PKCj or anti-total Akt antibodies and determi-
nation of the enzymatic activities was performed. As shown in
Fig. 2A, the stimulation of PI3-kinase and PKCj activities in
response to insulin was not a¡ected by pretreatment with ML-
9, however insulin-induced Akt activity was completely abol-
ished in the presence of the inhibitor (Fig. 2B). In addition,
cell lysates were analysed by Western blotting with the anti-
phospho Akt antibodies for both regulatory residues Ser473
and Thr308, as well as with the total and isoform-speci¢c Akt
antibodies. Upon insulin stimulation, Akt/PKB was highly
Fig. 1. LY294002 but not rapamycin inhibits insulin-stimulated glu-
cose uptake. A: Rat primary brown adipocytes were treated or not
with 10 WM LY294002 (LY) or 25 ng/ml rapamycin (R) for 30 min
before being stimulated with insulin (10 nM) for a further 30 min.
Glucose uptake was measured the last 10 min by incorporation of
2-deoxy-D-[1-3H]glucose into the cells. Results are expressed as dis-
integration per min per 1U106 cells and are the mean þ S.E.M.
(n = 8) for duplicate samples from four independent experiments.
Statistical signi¢cance was tested with a one-way analysis of var-
iance followed by the protected least-signi¢cant di¡erent test, where
di¡erences between values in the presence of insulin vs. control is
represented by (*) and di¡erences between values in the presence
of insulin plus LY vs. insulin is represented by (O) ;*,OP6 0.01.
B: Brown adipocytes were treated as above except that insulin stim-
ulation was for 5 min. Cells were then lysed and proteins assayed
for phospho-Akt(Ser473) and phospho-p70S6 kinase levels by West-
ern blot, or for PI3-kinase activity after immunoprecipitation with
anti-Tyr(P) antibody.
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Ser-phosphorylated, and in a lower extent, Thr-phosphorylat-
ed. ML-9 inhibited Ser473 phosphorylation in a dose-depen-
dent manner but had no e¡ect on Thr308 phosphorylation
(Fig. 2C). Moreover, antibodies raised against the total Akt,
and the isoforms Akt1 and Akt2 revealed a mobility shift
when cells were stimulated with insulin, this e¡ect being not
observed under pretreatment with ML-9 at 300 WM, when
dephosphorylation at Ser473 occurred. The presence of ML-
9 also precluded insulin-stimulated p70S6-kinase phosphory-
lation (Fig. 2C). Therefore, ML-9 blocks Akt and p70S6-ki-
nase but neither PI3-kinase nor PKCj stimulation by insulin,
that allows us to di¡erentiate between PI3-kinase-PKCj path-
way and Akt-dependent e¡ects of insulin.
To evaluate the signi¢cance of Akt in the signalling path-
way by which insulin induces glucose transport in brown adi-
pocytes, we performed series of experiments pretreating cells
with various doses (30^300 WM) of ML-9 for 10 min followed
by stimulation with insulin (10 nM) for a further 30 min.
Glucose uptake was measured during the last 10 min by in-
corporation of 2-deoxy-D-[1-3H]glucose into cells. Basal glu-
cose uptake either in the absence or presence of ML-9 was
also determined. As depicted in Fig. 3A, ML-9 had not e¡ect
on the basal glucose uptake, even at the highest dose used
(300 WM). However, insulin-induced glucose uptake was re-
duced about 50% by 30 WM ML-9. Higher concentrations of
the Akt inhibitor totally precluded glucose transport stimu-
lated by insulin, decreasing glucose uptake to basal levels.
Insulin increases glucose incorporation mainly because its
ability to recruit the insulin-responsive glucose transporter
GLUT4 from intracellular compartments to the cell surface.
We wanted to determine whether the inhibitory e¡ects of ML-
9 on insulin-induced glucose uptake were due to an impaired
capacity of insulin for GLUT4 translocation. Brown adipo-
cytes were treated as above and subjected to subcellular frac-
tionation. Western blot protein analysis with anti-GLUT4
antibody indicated that insulin increased by 3-fold GLUT4
translocation to plasma membrane with a concomitant de-
crease of GLUT4 amount in the internal membrane. Both
e¡ects were prevented by ML-9 in a concentration-dependent
manner (Fig. 3B), what indicates that the Akt inhibitor pre-
cludes insulin-induced glucose uptake by preventing GLUT4
translocation to the plasma membrane. However, neither ML-
9 alone or in the presence of insulin modi¢ed GLUT1 protein
content at the plasma membrane (data not shown). Caveolin-
1, an integral protein from caveolae implicated in cellular
transport processes [35] was used as a marker protein of plas-
ma membrane and its expression remained essentially unal-
tered under the di¡erent treatments used (Fig. 3B).
To validate the data on insulin-induced glucose uptake ob-
tained with the chemical inhibitor of Akt, ML-9, we decided
to block Akt by transfection with a dominant-negative Akt
construct (vAkt). Since immortalised brown adipocytes also
express GLUT4 and have higher transfection e⁄ciency than
primary brown adipocytes, these cells were transiently trans-
Fig. 2. E¡ect of ML-9 on insulin signalling pathway. A, B: Primary brown adipocytes were preincubated or not with ML-9 for 10 min at the
doses indicated were further treated with insulin for 5 min. Cells were then lysed and either immunoprecipitated with anti-Akt or PKCj anti-
bodies and the resulting immune complexes assayed for MBP phosphorylation, or immunoprecipitated with anti-Tyr(P) antibody and assayed
for PI3-kinase activity. Results shown are representative of at least four independent experiments. C: Cells were pretreated or not with ML-9
(30^300 WM) for 10 min before being stimulated with insulin for 5 min. Cells lysates were analysed by Western blotting with the corresponding
antibodies against phospho-Akt(Ser473), phospho-Akt(Thr308), total Akt, Akt1 and Akt2 and phospho-p70S6K.
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fected with 10 Wg of pSG5-PKB-CAAX (vAkt) or an empty
vector together with 2 Wg of GFP to monitor transfection
e⁄ciency. Cells were cultured for 24 h in 10% FCS medium,
overnight serum-starved and stimulated or not with insulin
(100 nM) for 30 min, with the glucose uptake determined
during the last 10 min by incorporation of 2-deoxy-D-[1-3H]-
glucose as described above (Fig. 3C). In this cell line insulin
increased glucose uptake by nearly 2-fold, this e¡ect being
almost completely abolished in the presence of an Akt protein
with dominant-negative activity. Furthermore, we co-trans-
fected HeLa cells, that do not constitutively express GLUT4
but are insulin-responsive cells [36], with 10 Wg of a GFP-
tagged GLUT4 construct together with 10 Wg of the vAkt
or an empty vector. Cells were cultured for 24 h in 10%
FCS medium, overnight serum-starved and stimulated or
not with insulin (500 nM) for 30 min, and the translocation
of GFP-GLUT4 was determined with £uorescence microsco-
py (Fig. 3D). The characteristic ring of GLUT4 staining at the
periphery of the cells in response to insulin stimulation was
quantitated either in the absence (V) or in the presence of
vAkt. Blocking Akt with a vAkt construct signi¢cantly pre-
cluded GFP-GLUT4 translocation to the plasma membrane.
These data obtained with vAkt on impairment of insulin-in-
duced glucose uptake and GLUT4 translocation in immortal-
ised brown adipocytes and HeLa cells, respectively, are con-
¢rmatory of those obtained with ML-9 in primary brown
adipocytes.
3.2. Akt is involved in insulin-induced GLUT4 gene expression
The results described above support the involvement of Akt
in the pathway leading to glucose uptake under acute insulin
stimulation. Insulin also plays a long-term role increasing
GLUT4 levels of a PI3-kinase-dependent mechanism [26]. Be-
cause Akt is an e¡ector downstream PI3-kinase we wanted to
Fig. 3. ML-9 inhibits insulin-stimulated glucose uptake and GLUT4 translocation in a similar fashion that dominant-negative Akt. A: Primary
brown adipocytes were preincubated for 10 min with increasing doses of ML-9 (0^300 WM) before 30 min of stimulation in the absence (none)
or in the presence of 10 nM insulin (Ins). Glucose uptake was measured the last 10 min by incorporation of 2-deoxy-D-[1-3H]glucose into the
cells. Results are expressed as disintegration/min/1U106 cells and are the mean þ S.E.M. (n = 8) for duplicate samples from four independent ex-
periments. B: Cells were treated as described above and collected for subcellular fractionation. 10 Wg of internal and plasma membrane proteins
from each condition were subjected to SDS^PAGE, blotted on to nylon membrane, immunodetected with anti-GLUT4 and anti-Caveolin-1
antibodies and developed with ECL chemiluminescence. A representative experiment out of four is shown. C: Immortalised brown adipocytes
were transiently transfected with 10 Wg of vAkt (pSG5-PKB-CAAX, a dominant-negative form of Akt) or with the empty vector (V). 2 Wg of
GFP were added to each dish to monitor transfection e⁄ciency. Cells were cultured for 24 h in 10% FCS medium, overnight serum-starved
and stimulated or not with insulin (100 nM) for 30 min, with the glucose uptake determined during the last 10 min as described in A. Results
are expressed as disintegration/min/1U106 cells and are the mean þ S.E.M. (n = 8) for duplicate samples from four independent experiments.
Statistical signi¢cance was tested with a one-way analysis of variance followed by the protected least signi¢cant di¡erence test, where di¡erences
between values in the presence of insulin vs. control is represented by (*) and di¡erences between values in the presence of insulin plus vAkt
vs. insulin is represented by (O);*,OP6 0.01. D: HeLa cells were transiently co-transfected with 10 Wg of GFP-tagged GLUT4 together with 10
Wg of vAkt or with the empty vector (V). Cells were cultured for 24 h in 10% FCS medium, overnight serum-starved and stimulated or not
with insulin (500 nM) for 30 min, being GLUT4 translocation observed under £uorescence microscopy. Cells were scored as positive for
GLUT4 translocation if they were observed to have a ring of £uorescence at the periphery. The percentage of positive cells are means þ S.E.M.
for several ¢elds for duplicate dishes from two independent experiments. Statistical signi¢cance was tested as in C.
FEBS 24785 9-4-01
R. Hernandez et al./FEBS Letters 494 (2001) 225^231 229
explore the possible implication of Akt in long-term e¡ects of
insulin on GLUT4 gene expression blocking Akt activity by
two di¡erent ways: (1) using the chemical compound ML-9,
and (2) transfecting cells with an Akt protein with dominant-
negative activity. Brown adipocytes were treated for 6 h with
insulin in the absence or presence of ML-9 or LY294002, and
GLUT4 mRNA levels were analysed by Northern blot. As
shown in Fig. 4A, insulin increased by 3-fold GLUT4
mRNA levels and this e¡ect was abolished by the Akt inhib-
itor, in a similar fashion as the inhibitor of PI3-kinase did.
Moreover, primary brown adipocytes were transiently co-
transfected with 10 Wg of GLUT4-CAT and 10 Wg of vAkt
or a dominant-negative p85 construct (vp85) or an empty
vector. After transfection, cells were fed with serum-free me-
dium and cultured for 24 h in the absence or presence of
insulin. As depicted in Fig. 4B, insulin stimulation of
GLUT4-CAT fusion gene activity (4-fold increase) was almost
precluded upon co-transfection with either the vAkt or the
vp85 construct. Both approaches suggest a role for Akt,
downstream PI3-kinase, in insulin-induced GLUT4 gene ex-
pression.
4. Discussion
The insulin-stimulated PI3-kinase pathway seems to be the
main route involved in glucose uptake in most insulin-respon-
sive cells, including brown adipocytes. However, downstream
or alternative pathways leading to this metabolic e¡ect of
insulin remain to be completely established. In this work we
have investigated the contribution of Akt to insulin stimula-
tion of glucose transport in brown adipocytes by two ap-
proaches, (1) using ML-9, proposed as a chemical inhibitor
of Akt activity in a recent paper [14], and (2) blocking Akt
with an Akt protein with dominant-negative activity. ML-9
treatment of primary brown adipocytes produced a complete
inhibition of insulin-stimulated glucose uptake and an impair-
ment of the redistribution of GLUT4 from internal membrane
to plasma membrane in response to insulin. However, ML-9
was not a¡ecting the glucose transport machinery per se since
basal glucose uptake remained unchanged in its presence. Our
results in primary brown adipocytes are in conformity with
those reported in isolated fat cells [14]. All the results pre-
sented with the chemical inhibitor have been validated with
the dominant-negative construct of Akt (vAkt). In this re-
gard, vAkt transiently transfected precluded insulin-stimula-
tion of glucose uptake in immortalised brown adipocytes and
insulin-induced GFP-tagged GLUT4 translocation to the
plasma membrane in HeLa cells.
Pretreatment with ML-9 did not a¡ect insulin-stimulated
PI3-kinase nor PKCj activities, however, completely inhibited
(1) insulin-stimulated Akt kinase activity immunoprecipitated
with anti-total-Akt antibody, (2) Akt phosphorylation by in-
sulin at the regulatory residue Ser473 but not at Thr308, (3)
insulin-induced mobility shift in Akt1, Akt2 and total Akt
separated in polyacrylamide gels and (4) phosphorylation of
p70S6-kinase by insulin. We did not detect inhibition of PI3-
kinase by ML-9, in agreement with Smith’s data [14], but we
found that ML-9 prohibited Akt activity and the phosphory-
lation of Akt at Ser473, in contrast with the lack of e¡ect of
this compound on Akt phosphorylation at the same dose
found [14]. These results indicate that autophosphorylation
of Akt on the hydrophobic site (Ser473) is not been produced
when Akt is catalytically incompetent (by treatment with ML-
9), as recently has been proposed [37]. Furthermore, our data
agree with the inhibition produced by ceramide on Akt acti-
vation by dephosphorylation at Ser473, but not at the Thr308
residue, in TF-1 cells treated with the colony-stimulating fac-
tor [38]. Phosphorylation of p70S6-kinase by insulin also re-
sulted in inhibition in the presence of ML-9, but this e¡ect is
probably the consequence of Akt inactivation, as recently
proposed [11]. Insulin-induced glucose uptake in brown adi-
pocytes seems to be independent of p70S6-kinase activation,
Fig. 4. Akt is involved in insulin-induced GLUT4 gene expression. A: Primary brown adipocytes (20 h serum-deprived) were treated for 6 h
with 10 nM insulin, either in the absence or presence of 10 WM LY294002 (LY) or 300 WM ML-9, and untreated cells were used as control.
Total RNA (10 Wg) from each condition was subjected to Northern blot analysis and hybridised with GLUT4 and GLUT1 probes. An equal
amount of loaded RNA was assessed by hybridisation with 18S RNA probe. Autoradiograms from a representative experiment out of four are
shown. B: Primary brown adipocytes were transiently co-transfected with 10 Wg of GLUT4-CAT together with 10 Wg of vp85 (a dominant-neg-
ative form of the regulatory subunit of PI3-kinase) or vAkt or with the empty vector (V). 2 Wg of DNA-Lgal were added to each dish to moni-
tor transfection e⁄ciency. After transfection cells were treated or not for 24 h with 10 nM insulin and at the end of the culture time collected
and assayed for CAT activity. A representative experiment out of four is shown.
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as demonstrated by the use of the speci¢c inhibitor rapamy-
cin. PKCj could be another PI3-kinase downstream target
involved in insulin-induced glucose uptake in adipocytes
[16,17], but ML-9 did not inhibit this step although we have
recently reported an inhibition of this enzyme with okadaic
acid that precluded insulin-stimulated glucose transport.
Although the contribution of Akt to insulin-induced glucose
uptake is controversial, with both positive and negative evi-
dences in the literature [9,11^13], this paper indicates that Akt
activation seems to be an absolute requirement for insulin-
induced glucose uptake in foetal brown adipocytes.
Furthermore, this work describes for the ¢rst time an in-
hibitory e¡ect of long-term treatment with ML-9 in insulin
induction of GLUT4 gene expression. Since long-term treat-
ment with ML-9 produced down-regulation of the GLUT4
mRNA accumulation, inactivation of Akt, and possibly its
translocation to the nucleus as recently proposed [39], would
be producing this e¡ect. This data suggest a role of Akt at the
transcriptional level in brown adipocytes. To test this hypoth-
esis we performed GLUT4-CAT transactivation experiments
in the presence of the vAkt construct. Co-transfection with
vAkt precluded insulin stimulation of GLUT4 promoter ac-
tivity in a similar fashion as vp85 did, indicating that PI3-
kinase/Akt pathway is regulating GLUT4 gene transcription
by insulin. Akt has been involved in the insulin-induced ex-
pression of other glucose transporters, such as GLUT1 in
hepatoma cells and GLUT3 in skeletal muscle [27,28]. This
work demonstrates for the ¢rst time that GLUT4 gene is
transcriptionally regulated by insulin thought Akt activation,
although the speci¢c transcription factors involved remain to
be established.
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